Johnson & Johnson (NYSE: JNJ) officially spun off its consumer health business this month, creating the largest U.S. initial public offering since 2021. Kenvue (NYSE: KVUE) began trading as a stand-alone business and gives healthcare investors a new stock to potentially add to their portfolios. It now controls the production and sale of top products like Band-Aid, Tylenol, and Neutrogena, and it will offer a dividend, just as its parent company does.

There are some intriguing aspects to this business that could make it an attractive investment. Is this a stock worth buying right now?

Although Kenvue is technically a separate company, Johnson & Johnson will still play a big role in its operations; the healthcare company will own a 90% stake in the business.

Continue reading

Source Fool.com